Jefferies 2012 Global Healthcare Conference Review.
Datamonitor attended the Jefferies 2012 Global Healthcare Conference held in London over November 14–15, 2012.
This analysis review covers the key highlights of the conference:
- Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS
- The status of late-stage agents such as Roche’s Perjeta (pertuzumab) for breast cancer, Novo Nordisk’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec + insulin aspart) for type 2 diabetes, ImmunoGen’s trastuzumab emtansine (TDM1) for breast cancer, Rigel’s fostamatinib for rheumatoid arthritis, Aegerion’s lopidomide for homozygous familial hypercholesterolemia, NPS Pharmaceuticals’ Gattex (teduglutide) for short bowel syndrome and Natpara (recombinant human parathyroid hormone [1-84]) for the treatment of adult hypoparathyroidism, Cubist’s ceftolozane/tazobactam for complicated urinary tract infections and complicated intra-abdominal infections, and United Therapeutics’ implantable infusion
Download our White Paper for the full analyst review.